CSPC INNOVATION PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.7 CNY | -0.84% |
|
-4.09% | +0.60% |
| Apr. 22 | CSPC Innovation Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 19 | China's drugmakers can't sell mRNA shots but haven't quit yet | RE |
| Sales 2024 * | 3.06B 423M | Sales 2025 * | 4.09B 565M | Capitalization | 43.12B 5.95B |
|---|---|---|---|---|---|
| Net income 2024 * | 722M 99.7M | Net income 2025 * | 952M 131M | EV / Sales 2024 * | 13.6 x |
| Net cash position 2024 * | 1.57B 217M | Net cash position 2025 * | 5B 690M | EV / Sales 2025 * | 9.32 x |
| P/E ratio 2024 * |
59.8
x | P/E ratio 2025 * |
47
x | Employees | 1,887 |
| Yield 2024 * |
0.87% | Yield 2025 * |
0.42% | Free-Float | 22.71% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.84% | ||
| 1 week | -4.09% | ||
| Current month | -10.42% | ||
| 1 month | -4.63% | ||
| 3 months | +20.00% | ||
| 6 months | -0.43% | ||
| Current year | +0.60% |
1 week
30.16
33.07
1 month
30.1635.77
Current year
19.6935.77
1 year
9.0940.62
3 years
5.3640.62
5 years
5.3640.62
10 years
4.9840.62
| Managers | Title | Age | Since |
|---|---|---|---|
Feng Han
CEO | Chief Executive Officer | 50 | 15-12-31 |
Long Dai
DFI | Director of Finance/CFO | 32 | 23-04-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Dong Pan
CHM | Chairman | 55 | - |
Huai Yu Wang
BRD | Director/Board Member | 61 | 15-12-31 |
Ji Yong Zhang
CHM | Chairman | - | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 30.7 | -0.84% | 8,538,318 |
| 24-05-23 | 30.96 | -0.03% | 8,276,334 |
| 24-05-22 | 30.97 | -3.94% | 20,020,080 |
| 24-05-21 | 32.24 | -0.80% | 9,525,346 |
| 24-05-20 | 32.5 | +1.53% | 15,366,890 |
End-of-day quote Shenzhen S.E., May 23, 2024
More quotes
CSPC Innovation Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of functional ingredients. The Company operates two segments. Functional Ingredients segment mainly provides caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, theophylline, theobromine, pentoxifylline, doxofylline, and biological enzymes. Health Food Products segment mainly provides Guoweikang Vitamin C tablets, Guoweikang B vitamin lozenges, and others. The Company mainly conducts businesses within the domestic market.
Sector
Food Processing
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
30.7
CNY
Average target price
40.1
CNY
Spread / Average Target
+30.61%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.60% | 5.95B | |
| +13.97% | 8.2B | |
| +5.29% | 7.61B | |
| -6.04% | 3.72B | |
| -10.75% | 3.57B | |
| -7.53% | 1.27B | |
| -29.55% | 1.07B | |
| +14.57% | 988M | |
| -12.85% | 890M | |
| -18.06% | 789M |
- Stock Market
- Equities
- 300765 Stock
